The Michael J. Fox Foundation (MJFF) is expediting Parkinson’s disease research, working tirelessly to advance global opportunities in neuroscience.
-
Resources for Researchers: Data, Tools, Study Recruitment & More
MJFF is committed to providing support and resources to those invested in Parkinson’s research— across academia, industry, government venture capital and more.
-
Biospecimen Library
MJFF makes data and biospecimens available from select Parkinson's studies for discovery and validation research.
-
Research Tools Catalog
The Research Tools Catalog is an interactive catalog that hosts all tools and models that MJFF makes available through our Research Tools Program.
-
Data Resources
We collaborate with the research community to collect and distribute a multitude of data resources to accelerate therapeutic development.
-
Study Recruitment
MJFF invests in the infrastructure and resources to equip research teams with the tools to recruit and retain participants for their trials. Ready to start recruiting?
-
-
Funding Opportunity: Parkinson's Disease Therapeutic Pipeline Program
Funding is available from MJFF’s Therapeutics Pipeline Program to support therapeutic development of treatments that may reduce, slow or prevent disabling motor or non-motor symptoms of Parkinson’s disease not well managed by current treatments.
- This funding program aims to accelerate pre-clinical and clinical therapeutic development for Parkinson’s disease treatment
- Applications are accepted on a rolling basis to allow for faster feedback from MJFF on proposed projects
- Open to industry and industry + academia partnerships that are capable of further commercial development of a promising intervention
-
Landscape Intelligence Reports
MJFF provides Parkinson’s disease landscape reports to the researcher community including a target report, biomarker report, and clinical pipeline report - highlighting the latest advancements in therapeutic development.
-
Parkinson's Priority Therapeutic Clinical Pipeline Report
This report tracks therapies currently in clinical development for Parkinson’s disease as of late March 2024. It includes brief rationale and progress in key pipelines of therapeutic interest along with detailed listings of specific therapies, current development status and information about MJFF support (funding and/or non-funding connections).
-
Parkinson's Disease Biomarker Report
This report provides an overview of the Parkinson’s disease biomarkers landscape, with a focus on biochemical and molecular based assays that MJFF staff are currently monitoring. It is intended to reflect biomarkers at various stages of development and validation for the indicated intended uses (e.g., diagnosis, monitoring, etc.)
-
Parkinson's Disease Target Report
This report includes profiles of emerging and advanced targets along with a summary of the current status of the target as it relates to therapeutic devlopment, its connection to Parkinson's disease, MJFF’s investments to date and companies working on the respective target.
-
-
Parkinson's Disease Biomarker Found (aSyn-SAA)
Emerging evidence shows that alpha synuclein seed amplification assays (SAAs) have the potential to differentiate people with Parkinson's disease from healthy controls
-
Parkinson's Disease is Moving Towards a Biologic Staging System
Recent biomarker advancements enable accurate detection of pathological α-synuclein in cerebral spinal fluid (CSF), suggesting redefining Parkinson's disease and dementia with Lewy Bodies as "neuronal α-synuclein disease" (NSD) based on in vivo detection, regardless of specific clinical symptoms. This proposal introduces an integrated staging system, NSD-ISS, categorizing individuals by α-synuclein presence and functional impairment degree, aiming to facilitate early intervention trials and research.
-
BREAKING NEWS: Congress Passed the National Plan to End Parkinson's Act
On May 23, 2024, The U.S. Senate today unanimously passed the National Plan to End Parkinson’s Act, the first-ever federal legislation dedicated to ending Parkinson’s disease, sending the bill to President Biden’s desk to be signed into law. The bill passed with overwhelming bipartisan support in the U.S. House of Representatives last December.
-
The Parkinson's Disease Research Exchange
The Parkinson’s Disease Research Exchange (PDRx) is a global network of scientists from academic labs, pharma/biotech companies, CROs and investors focused on assessing the current state of Parkinson's disease research, identifying key challenges, and translating findings into improved therapies.
Meetings are held virtually every Wednesday at 11:00 AM Eastern Standard Time (US).
Questions?
Get in Touch: researchpartnerships@michaeljfox.org